key: cord-1017652-nv70mlae authors: Teixeira da Silva, Jaime A. title: Convalescent plasma: A possible treatment of COVID-19 in India date: 2020-04-15 journal: Med J Armed Forces India DOI: 10.1016/j.mjafi.2020.04.006 sha: 2786292953a9a7dfa355446b2d9a9358a29c95e0 doc_id: 1017652 cord_uid: nv70mlae Abstract In India, SARS-CoV-2 virus–induced coronavirus disease 2019 (COVID-19) has already infected close to 5500 people, causing the death of 164. While these numbers are not comparable with values observed for the USA, Italy, or Spain, given the population of India, and the fact that the pandemic is now in an exponential stage of growth, the risks of a contagion that affects a large sector of the Indian population are real. There are no current effective strategies to prevent the spread, other than minimizing contact through social distancing, while no fully effective drugs to prevent or treat COVID-19 exist, although several candidate drugs and repurposed antiviral and immune-modulating pharmacotherapies are being tested or in compassionate use. One postexposure prophylaxis, convalescent (immune) plasma (CP), has shown some success in China and previously in the cure and therapy of other coronaviruses, SARS-1 and Middle East respiratory syndrome. Drawn from current patients who are infected with COVID-19, its CP (human anti–SARS-CoV-2 plasma) might be one way to modulate the infectivity of this virus or its effects postinfection. Chatterjee et al. 1 modeled the expected outcome of COVID-19 in India with the objective of assessing its impact to appreciate the magnitude of the effect on Indian healthcare services. Using data from March 31 (2020), which according to JHU indicates 330 infections in India, Chatterjee et al. 1 found that, among 11 quarantine scenarios, with 50% effective quarantine, 4412 citizens in India would become infected, while 10% effective quarantine would result in 521 million infections. These grim numbers suggest that solutions other than social distancing are urgently needed to combat the epidemic and to minimize the loss of life. Lessons learned thus far from the largest outbreaks of this pandemic in China, the US, Italy, and Spain reveal that there is still no cure, although several possible drugs and novel agents, which have not been clinically tested, are available through compassionate use, or as repurposed antiviral and immune-modulating pharmacotherapies. 2 India is likely to also be testing such repurposed drugs, but these can carry risks. A search on PubMed for the term "COVID-19" reveals close to 2900 studies published on this disease, with countless others on preprint servers such as bioRxiv or medRxiv. The wealth of data and the speed at which information related to all aspects of COVID-19 is astonishing, and historical. MJAFI1188_proof ■ 15 April 2020 ■ 1/ 2 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 One of the hopeful treatments that has emerged is convalescent plasma (CP), or immune plasma. CP, which is plasma that is collected from an infected individual, such as by COVID-19 (i.e., human antieSARS-CoV-2 plasma), is then transfused into infected patients as a postexposure prophylaxis. 3 Unlike immunoglobulin (IgG)-derived antibodies such as plasma-derived monoclonal antibodies, CP is a passive antibody therapy that showed some success as a neutralizing antibody against other coronavirus epidemics, SARS-1 and Middle East respiratory syndrome (MERS), in the first two decades of the 2000s. CP-derived antibodies can neutralize a virus by preventing replication (e.g., by complement activation or phagocytosis) or by binding without interfering with replication. 4 In China, five critically ill patients infected with COVID-19 (also with acute respiratory distress syndrome) received a transfusion of SARS-CoV-2especific IgG (binding titer > 1:1000; neutralization titer > 40) 10e22 days after admission. 5 Their clinical status improved, with three having been discharged after 51e55 days of hospitalization. It should be noted that these patients were also supported by a mechanical ventilator and had also received antiviral agents (combinations of lopinavir, ritonavir, interferon a-1b, favipiravir, arbidol, and/or darunavir) and methylprednisolone, a steroid. Globally, there is currently no effective postinfection prophylaxis for the treatment of COVID-19, although some drugs are being repurposed. There are also no antibodies for the prevention of COVID-19, and it will likely be months before antibodies emerge from clinical trials. CP, a postinfection treatment, has shown limited and moderate success, previously for SARS-1 and MERS, and for COVID-19 in China, and could serve as a short-term solution to suppress mortality rates in India. As the number of infections increases, the CP of infected patients could be donated or harvested for simultaneous treatment or future use until an effective antibody is discovered. The author contributed solely to the intellectual discussion underlying this study, literature exploration, writing, review, and editing and accepts responsibility for the content and interpretation. Not applicable. The author declares no conflicts of interest relevant to this topic. r e f e r e n c e s 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 Healthcare impact of COVID-19 epidemic in India: a stochastic mathematical model Review of emerging pharmacotherapy for the treatment of coronavirus disease 2019 Deployment of convalescent plasma for the prevention and treatment of COVID-19 Fcmediated antibody effector functions during respiratory syncytial virus infection and disease Treatment of 5 critically ill patients with COVID-19 with convalescent plasma